If mTOR pathway activation is a mechanism by which body fatness influences breast cancer risk, the association of body fatness in relation to mTOR activation should be observed in postmenopausal women with ER+ tumors for obesity defined by high BMI, as the epidemiologic evidence indicates [2–5]. This evidence concerns the gene MTOR and obesity due to melanocortin 4 receptor deficiency.